LepB

LepB

LepB is a bacterial signal peptidase I enzyme responsible for the proteolytic removal of N-terminal signal peptides from preproteins during translocation across the inner membrane. It plays a central role in post-translational modification and secretion in organisms such as Escherichia coli, Bacillus subtilis, Pseudomonas aeruginosa, and many other Gram-negative and Gram-positive bacteria. LepB function is integral to processes that involve the Sec (protein translocation), Tat (protein export), and signal recognition particle pathways, linking membrane protein biogenesis with periplasmic and secreted proteome maturation.

Function and Biological Role

LepB catalyzes cleavage of signal peptides after recognition of signal peptide motifs and positions the mature domain for folding in the periplasm or extracellular milieu, cooperating with chaperones such as DnaK, GroEL, and periplasmic folding factors like SurA and Skp. In pathogens including Salmonella enterica, Neisseria meningitidis, and Staphylococcus aureus, LepB-mediated processing activates virulence factors, adhesins, and toxins exported via the Type II secretion system, Type V secretion system, and general secretory pathways. LepB activity influences envelope biogenesis and cell division machinery that involve proteins like FtsZ and Lpp; disruptions perturb outer membrane assembly coordinated by complexes such as Bam complex and Lpt pathway components. In symbiotic bacteria associated with hosts like Rhizobium leguminosarum and Vibrio fischeri, LepB contributes to secretion of effectors required for mutualistic interactions.

Structure and Mechanism

LepB is an integral membrane serine protease with one or more transmembrane helices anchoring an extracytoplasmic catalytic domain that harbors the conserved catalytic dyad or triad (including a nucleophilic serine). Structural studies using X-ray crystallography and cryo-electron microscopy of homologous signal peptidases from organisms like Thermotoga maritima and Streptococcus pneumoniae reveal a globular peptidase fold resembling members of the peptidase family S26 and an active site pocket that recognizes signal peptide cleavage motifs (the −1, −3 rule). Substrate binding orients the signal peptide helix within a hydrophobic groove adjacent to key residues; mechanistic proposals invoke acyl-enzyme intermediates analogous to classical serine protease catalysis characterized in enzymes studied by groups at institutions such as Max Planck Society and European Molecular Biology Laboratory. Inhibitor-bound structures with antibiotics and peptidomimetics demonstrate how small molecules and natural products can block catalysis, informing drug discovery programs at organizations like GlaxoSmithKline and Novartis.

Genetics and Expression

The lepB gene is typically essential and conserved across bacterial phyla, with orthologs cataloged in genomic databases from model organisms such as Escherichia coli K-12 and environmental isolates sequenced by consortia including Human Microbiome Project and Global Microbial Identifier. lepB is commonly located in operons or genomic contexts adjacent to secretion-related genes and is regulated at the transcriptional and translational levels by promoters recognized by sigma factors such as RpoD and stress-responsive sigma factors like RpoE under envelope stress. Expression modulation occurs in response to stimuli involving two-component systems such as CpxAR and Rcs phosphorelay, which alter periplasmic folding load. Mutational analyses, including targeted allelic replacement in strains developed at institutions like Cold Spring Harbor Laboratory and University of California, Berkeley, reveal that point mutations in conserved catalytic residues abrogate viability or produce temperature-sensitive phenotypes.

Clinical Significance and Pathogenesis

Because LepB processes exported virulence determinants, it is implicated in the pathogenesis of infections caused by pathogens including Escherichia coli O157:H7, Pseudomonas aeruginosa PAO1, Helicobacter pylori, and Vibrio cholerae. Inhibiting LepB can attenuate secretion of toxins such as those encoded by plasmids found in Enteropathogenic E. coli and can disrupt maturation of surface antigens targeted by host immunity, affecting outcomes studied in animal models at centers like National Institutes of Health and Wellcome Trust. LepB has therefore attracted interest as an antibacterial target; small-molecule inhibitors and peptide-based inhibitors have been developed and optimized in preclinical programs at academic laboratories and industry partners like AstraZeneca and Pfizer. Resistance mechanisms and compensatory pathways involving proteases such as DegP and OmpT complicate therapeutic strategies, and clinical translation requires consideration of broad-spectrum effects on commensal bacteria cataloged by projects such as MetaHIT.

Methods of Study and Experimental Tools

Experimental approaches to study LepB include biochemical assays using fluorogenic peptides and radiolabeled substrates developed in core facilities at institutions like Harvard Medical School, structural determination by X-ray crystallography at synchrotrons operated by European Synchrotron Radiation Facility and Advanced Photon Source, and single-particle cryo-EM workflows at centers such as EMBL and National Center for CryoEM. Genetic tools include gene knockouts, conditional expression systems using plasmids designed at Addgene, CRISPR interference adapted for bacteria from protocols by Broad Institute, and reporter fusions with enzymes like β-galactosidase or fluorescent proteins derived from Aequorea victoria GFP to monitor secretion efficiency. High-throughput screening for inhibitors leverages libraries from repositories such as PubChem and cheminformatics pipelines developed at European Bioinformatics Institute; mass spectrometry–based proteomics using instruments from Thermo Fisher Scientific quantifies processing events and substrates in comparative secretome analyses.

Category:Proteases Category:Bacterial proteins